{"id":6665,"date":"2024-11-21T14:54:34","date_gmt":"2024-11-21T13:54:34","guid":{"rendered":"https:\/\/beigen.vipdev.lndo.site\/us\/?post_type=publication&p=6665"},"modified":"2025-04-28T21:53:30","modified_gmt":"2025-04-28T19:53:30","slug":"response-characteristics-of-tislelizumab-combined-with-chemotherapy-in-first-line-treatment-of-locally-advanced-or-metastatic-non-squamous-non-small-cell-lung-cancer","status":"publish","type":"publication","link":"https:\/\/beonemedaffairs.com\/us\/publication\/response-characteristics-of-tislelizumab-combined-with-chemotherapy-in-first-line-treatment-of-locally-advanced-or-metastatic-non-squamous-non-small-cell-lung-cancer\/","title":{"rendered":"Response characteristics of tislelizumab combined with chemotherapy in first-line treatment of locally advanced or metastatic non-squamous non-small cell lung cancer\u00a0"},"content":{"rendered":"","protected":false},"template":"","post-tag":[],"class_list":["post-6665","publication","type-publication","status-publish","hentry","disease_state-non-small-cell-lung-cancer","molecule-tislelizumab"],"acf":[],"_links":{"self":[{"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/publication\/6665","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/publication"}],"about":[{"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/types\/publication"}],"wp:attachment":[{"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/media?parent=6665"}],"wp:term":[{"taxonomy":"post-tag","embeddable":true,"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/post-tag?post=6665"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}